Travis S P, Farrant J M, Ricketts C, Nolan D J, Mortensen N M, Kettlewell M G, Jewell D P
Gastroenterology Unit, John Radcliffe Hospital, Oxford.
Gut. 1996 Jun;38(6):905-10. doi: 10.1136/gut.38.6.905.
Simple criteria are needed to predict which patients with severe ulcerative colitis will respond poorly to intensive medical treatment and require colectomy.
To find out if the early pattern of change in inflammatory markers or other variables could predict the need for surgery and to evaluate the outcome of medical treatment during one year follow up.
51 consecutive episodes of severe colitis (Truelove and Witts criteria) affecting 49 patients admitted to John Radcliffe Hospital, Oxford.
Prospective study monitoring 36 clinical, laboratory, and radiographic variables. All episodes treated with intravenous and rectal hydrocortisone and 14 of 51 with cyclosporine.
Complete response in 21 episodes (< or = 3 stools on day 7, without visible blood), incomplete response in 15 (> 3 stools or visible blood on day 7, but no colectomy), and colectomy on that admission in 15. During the first five days, stool frequency and C reactive protein (CRP) distinguished between outcomes (p < 0.00625, corrected for multiple comparisons) irrespective of whether patients or the number of episodes were analysed. It could be predicted on day 3, that 85% of patients with more than eight stools on that day, or a stool frequency between three and eight together with a CRP > 45 mg/l, would require colectomy. For patients given cyclosporine, four of 14 avoided colectomy but two continued to have symptoms. After admission, complete responders remained in remission for a median nine months and had a 5% chance of colectomy. Incomplete responders had a 60% chance of continuous symptoms and 40% chance of colectomy.
After three days intensive treatment, patients with frequent stools (> 8/day), or raised CRP (> 45 mg/l) need to be identified, as most will require colectomy on that admission. The role of cyclosporine for treating severe colitis has yet to be defined. After seven days' treatment, patients with > 3 stools/day of visible blood have a 60% chance of continuous symptoms and 40% chance of colectomy in the following months.
需要简单的标准来预测哪些重症溃疡性结肠炎患者对强化药物治疗反应不佳并需要进行结肠切除术。
了解炎症标志物或其他变量的早期变化模式是否可以预测手术需求,并评估一年随访期间药物治疗的结果。
牛津约翰拉德克利夫医院收治的49例患者连续发生51次重症结肠炎发作(采用 Truelove 和 Witts 标准)。
前瞻性研究,监测36项临床、实验室和影像学变量。所有发作均采用静脉和直肠氢化可的松治疗,51例中有14例采用环孢素治疗。
21次发作完全缓解(第7天大便次数≤3次,无肉眼可见出血),15次发作部分缓解(第7天大便次数>3次或有肉眼可见出血,但未进行结肠切除术),15例在此次住院期间进行了结肠切除术。在前五天内,无论分析的是患者还是发作次数,大便频率和C反应蛋白(CRP)均可区分不同的结果(p<0.00625,经多重比较校正)。在第3天可以预测,当天大便次数超过8次,或大便频率在3至8次之间且CRP>45mg/l的患者中,85%需要进行结肠切除术。接受环孢素治疗的患者中,14例中有4例避免了结肠切除术,但2例仍有症状。入院后,完全缓解者的缓解期中位数为9个月,结肠切除的几率为5%。部分缓解者持续出现症状的几率为60%,结肠切除的几率为40%。
经过三天的强化治疗后,需要识别大便频繁(>8次/天)或CRP升高(>45mg/l)的患者,因为大多数此类患者在此次住院期间需要进行结肠切除术。环孢素治疗重症结肠炎的作用尚待明确。治疗七天后,每天大便次数>3次且有肉眼可见出血的患者在接下来的几个月中持续出现症状的几率为60%,结肠切除的几率为40%。